🔴 Teradyne is trading 6% down in after-hours trading as the reason for the decline remains unclear

Teradyne is trading at $304.65, down 5.88% from the regular-session close of $323.68; it reported Q3 results above analyst estimates, but the precise trigger for the decline remains unclear.

• Q3 revenue was $1.306 billion and non-GAAP EPS was $2.29; both exceeded the high end of Q3 guidance.
• Q4 guidance calls for revenue of $1.25–$1.35 billion and non-GAAP EPS of $1.95–$2.25.